FDA - A-T: Scientific and Medical Information

admin@ataxiatelangiectasia.es

ChromaDex wins orphan designation for rare ataxia drug
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia